

Deep Venous Thrombosis/Pulmonary Embolism

Iahn Gonsenhauser, MD, MBA
Associate Chief Quality Officer
Assistant Professor - Clinical
Division of Hospital Medicine
The Ohio State University Wexner Medical Center

Objectives


- Recognize common signs and symptoms of venous thromboembolism (VTE)
- Select appropriate diagnostic testing to identify VTE
- Appropriately assess risk for VTE
- Apply evidence based interventions in the treatment of VTE

Background

Venous Thromboembolism (VTE) encompasses:

- Deep Venous Thrombosis (DVT)
- Pulmonary Embolism (PE)

Superficial Phlebitis is not included in this term




James Heilman, MD

Blaussen.com staff (2014). "Medical gallery of Blaussen Medical 2014". *WikiJournal of Medicine* 1 (2).DOI:10.15347/wjvm/2014.010. ISSN 2002-4436.

Background

- 350,000 – 600,000 US cases annually
- Hospitalization is a major risk factor
- Among the leading causes of preventable hospital death
- 10-15% Mortality
- Requires extended therapeutic anticoagulation



Clinical Pearls

- 96% of DVTs occur in the Lower Extremities**
- 90% of Pulmonary Emboli originate from DVTs**
- 50% of proximal LE DVT will result in PE**
- About 1/3 of DVTs result in post-thrombotic syndrome 5yrs post event**

Recognizing VTE

Clinical Features of DVT

- Asymmetric swelling/edema (greater than 3cm)
- Asymmetric pitting edema
- Local pain/erythema
- Palpable cord
- Homan's Sign

Blawie.com staff (2014). "Clinical pearls of Review Medical 2014". Wikijournal of Medicine 1(2):102. doi:10.13181/wjor.2014.0201.102a.2014.0436

Recognizing VTE

Clinical Features Pulmonary Embolism

Symptoms:

- Chest Pain – Pleuritic
- Dyspnea
- Palpitation
- Cough
- Syncope


James Holman, MD

Recognizing VTE

Clinical Features Pulmonary Embolism

Diagnostic Findings:

- Tachypnea
- Tachycardia
- Parasternal Heave
- Increased JVP
- Pleural Friction Rub



James Holman, MD

Diagnosing DVT/PE

| | | |
|--------|--|--|
| Step 1 | Detailed History and Physical | Pretest Probability Low < 2 Moderate = 2-6 High > 6 |
| Step 2 | Apply a validated clinical prediction tool | |

| Well's Criteria | Criteria | Points |
|-----------------|---|--------|
| | Signs/Symptoms of DVT | 3 |
| | No other more likely diagnosis | 3 |
| | Tachycardia > 100 BPM | 1.5 |
| | Immobilization > 3 days or Surgery past 4 weeks | 1.5 |
| | Previous history of DVT/PE | 1.5 |
| | Hemoptysis | 1 |
| | Malignancy | 1 |

Identifying - DVT/PE

Testing Modality Depends on Pretest Probability

D-Dimer

Low

Used to rule-out DVT in individuals with low pretest probability

Identifying - DVT/PE

Testing Modality Depends on Pretest Probability

Compression Ultrasound

Intermediate /High

Ultrasonography is both sensitive and specific for DVT

Identifying - DVT/PE

Testing Modality Depends on Pretest Probability

VQ Scan/CT
Angiogram

High

CT Angiogram is the test of choice if no contraindications

VTE – A Common Case

A typical patient presentation or illness script for a patient presenting with VTE is as follows:

57 y/o male presents with 1 week of:

- right thigh pain and swelling
- no history of recent surgery, trauma, hospitalization, long distance travel or immobilization
- On exam: erythema of the right thigh and a palpable cord is noted

What is the appropriate test to order?

Treatment of DVT/PE

The goals of treatment for VTE are:

- Anticoagulation to prevent further clot generation
- Thrombolysis if the thrombus is large enough to cause hemodynamic compromise.

Treatment of DVT/PE

Agents for acute Anticoagulation to prevent further clot generation

- Unfractionated heparin
- Low molecular weight heparin
- Fondaparinux
- Rivaroxaban, Apixaban

Treatment of DVT/PE

The acute anticoagulants can be used for chronic anticoagulation, but they are less convenient due to their scheduling and mechanism of delivery (Injection)

Oral anticoagulants are the mainstay of therapy:

| | |
|---------------------|---------------------------|
| Coumadin (Warfarin) | Vitamin K Antagonist |
| Dabigatran | Direct Thrombin Inhibitor |
| Rivaroxaban | Direct Xa Inhibitor |
| Apixaban | |
| Edoxaban | |

Treatment of DVT/PE

Duration of Chronic Anticoagulation Therapy:

- Location – LE/UE/Distal/Proximal/PE
- Symptoms – Mild/Moderate/Severe
- Etiology – Provoked/Unprovoked
- History – Recurrent/Cancer-Associated


| | |
|-------------------------------|------|
| Distal LE No/Mild Symptoms | N/A |
| Distal LE Mod/Severe Symptoms | 3 mo |
| Proximal LE Provoked | 3 mo |
| Proximal LE Unprovoked | Ext |
| Recurrent Provoked | 3 mo |
| Cancer Associated | Ext |

Special Considerations

Inferior Vena Cava Filter

Only indicated for patients with acute pelvic or proximal leg DVT who:

- Cannot safely undergo anticoagulation due to bleeding risk
- Experiencing active bleeding.



Special Considerations

Sub-Massive Pulmonary Embolism

Acute PE causing:

- Observed Right Heart Strain/RV Dysfunction
- Or -
- Myocardial Necrosis
- May be evident on echocardiogram, CT, ECG

Special Considerations

Massive Pulmonary Embolism

Acute PE causing:

- Sustained hypotension
- Greater than 15 minutes
- May require inotropic support

Treatment of Submassive/Massive PE

If evidence of Shock, Respiratory Failure or Moderate to Severe RV Strain:

- Lytic therapy (Fibrinolysis)
- Catheter Based Therapy

Special Considerations

Hospitalized Patients

- 1% or more of admissions result in an HA-VTE
- Estimated to be among the most common preventable causes of hospital death

Failure Modes

- Inappropriate Risk Stratification
- Suboptimal PPx Ordering
- Failure to Administer Ordered PPx
- Incidental Identification


Hospitalized Patients

How to Protect Our Patients:

| LOW RISK | HIGH RISK | VERY HIGH RISK | | | | | | | | | | | | | | | | |
|---|--|---|--|------------------------------|------------------------------|--|------------------|--|------------------|--|----------------------------|----------------------------|----------------------------|----------------------------|---|--|--|--|
| <ul style="list-style-type: none"> • Must meet <u>all</u> three: <ul style="list-style-type: none"> • Ambulatory patient • NO additional VTE risk factors (see page 4) • Expected LOS < 48 hours Also consider: <ul style="list-style-type: none"> • Minor surgery in patient (same day surgery or OR time < 30 minutes) • NO additional VTE risk factors • On FULL anticoagulation | <ul style="list-style-type: none"> • All other patients who are NOT in the LOW, or VERY HIGH groups or are NOT receiving FULL anticoagulation • Most medical and surgical inpatients | <ul style="list-style-type: none"> • Bariatric Surgery and BMI ≥ 40 kg/m² • Hip, pelvic, or severe lower extremity fractures • Acute spinal cord injury (SCI) • Multiple major trauma (e.g., multiple fractures due to a fall or motor vehicle accident) • Abdominal or pelvic surgery for cancer • Neurosurgery • Stroke (within the last month) | | | | | | | | | | | | | | | | |
| PHARMACOLOGIC PROPHYLAXIS | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> • No pharmacologic prophylaxis | <table border="1"> <thead> <tr> <th>BMI < 40 kg/m²</th> <th>BMI ≥ 40 kg/m²</th> </tr> </thead> <tbody> <tr> <td>• Heparin 5,000 units SQ Q8H</td> <td>• Heparin 7,500 units SQ Q8H</td> </tr> </tbody> </table> | BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | • Heparin 5,000 units SQ Q8H | • Heparin 7,500 units SQ Q8H | <table border="1"> <thead> <tr> <th colspan="2">CrCl ≥ 30 mL/min</th> <th colspan="2">CrCl < 30 mL/min</th> </tr> <tr> <th>BMI < 40 kg/m²</th> <th>BMI ≥ 40 kg/m²</th> <th>BMI < 40 kg/m²</th> <th>BMI ≥ 40 kg/m²</th> </tr> </thead> <tbody> <tr> <td> <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q24H ◦ Neurosurgery ◦ Stroke ◦ Abdominal/pelvic surgery for cancer </td> <td> <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q12H </td> <td> <ul style="list-style-type: none"> • Heparin 5,000 units SQ Q8H </td> <td> <ul style="list-style-type: none"> • Heparin 7,500 units SQ Q8H </td> </tr> </tbody> </table> | CrCl ≥ 30 mL/min | | CrCl < 30 mL/min | | BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q24H ◦ Neurosurgery ◦ Stroke ◦ Abdominal/pelvic surgery for cancer | <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q12H | <ul style="list-style-type: none"> • Heparin 5,000 units SQ Q8H | <ul style="list-style-type: none"> • Heparin 7,500 units SQ Q8H |
| BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | | | | | | | | | | | | | | | | | |
| • Heparin 5,000 units SQ Q8H | • Heparin 7,500 units SQ Q8H | | | | | | | | | | | | | | | | | |
| CrCl ≥ 30 mL/min | | CrCl < 30 mL/min | | | | | | | | | | | | | | | | |
| BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | BMI < 40 kg/m ² | BMI ≥ 40 kg/m ² | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q24H ◦ Neurosurgery ◦ Stroke ◦ Abdominal/pelvic surgery for cancer | <ul style="list-style-type: none"> • Enoxaparin 40 mg SQ Q12H | <ul style="list-style-type: none"> • Heparin 5,000 units SQ Q8H | <ul style="list-style-type: none"> • Heparin 7,500 units SQ Q8H | | | | | | | | | | | | | | | |
| MECHANICAL PROPHYLAXIS | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> • Ambulation | <ul style="list-style-type: none"> • Ambulation • Use Sequential Compression Device (SCD) if drug therapy contraindication is documented | <ul style="list-style-type: none"> • Ambulation when patient is able • Use Sequential Compression Device (SCD) in <u>addition</u> to drug therapy or if drug therapy contraindication is documented | | | | | | | | | | | | | | | | |

Hospitalized Patients

Inpatient Post-Operative VTE Rate:



Conclusions

- Recognition of acute VTE requires careful history and physical exam
- Selection of appropriate diagnostic testing to identify VTE requires understanding and assessment of each patient's pretest probability
- VTE therapy is variable and is determined by specific features of the vTE event
- Hospitalized patients are at high risk for VTE and careful action must be taken to prevent avoidable harm

Case #1

- 45 year old woman with symptomatic gallstones
- Past medical history: hypertension, obesity (BMI 34)
- Plan: laparoscopic cholecystectomy (estimated 60 minutes)

What DVT prophylaxis do you recommend?

Modified Caprini Score

| 1 Point | 2 Points | 3 Points | 5 Points |
|------------------------------|--------------------------------|---------------------------|------------------------------|
| Age 41-60 | Age 61-74 | Age > 75 | Stroke < 1 month |
| Minor Surgery | Arthroscopic Surgery | History of DVT/PE | Arthroplasty |
| BMI > 25 | Major Open Surgery > 45 Min. | Family History of DVT/PE | Hip, Pelvis, or Leg Fracture |
| Swollen Legs | Laparoscopic Surgery > 45 Min. | Factor V Leiden | Acute Spinal Cord Injury |
| Varicose Veins | Malignancy | Prothrombin Gene Mutation | |
| Pregnancy or Postpartum | Confined to Bed > 72 Hours | Lupus Anticoagulant | |
| History of Miscarriage | Immobilizing Plaster Cast | Anticardiolipin Antibody | |
| Oral Contraceptives/Hormones | Central Venous Access | Elevated Homocysteine | |
| Sepsis in Last Month | | H.I.T | |
| Lung Disease in Last Month | | Other Thrombophilia | |
| Abnormal PFTs | | | |
| Acute Myocardial Infarction | | | |
| Heart Failure | | | |
| Inflammatory Bowel Disease | | | |
| Bed Rest | | | |

Case #1 General and Abdominal Surgery

- 1 point for age 45
- 1 point for BMI > 25
- 2 points for laparoscopic surgery > 45 minutes
- 4 points total
- Caprini score 0: no prophylaxis
- Caprini score 1-2: intermittent pneumatic compression
- Caprini score 3-4: LMWH, SQ heparin OR intermittent pneumatic compression
- Caprini score \geq 5: LMWH or SQ heparin PLUS intermittent pneumatic compression

Case #2

- 63 year old man with back pain and spinal stenosis
- Past medical history: diabetes
- Plan: laminectomy

What DVT prophylaxis do you recommend?

Case #2: Spinal Surgery

- Standard risk patients: intermittent pneumatic compression
- High risk patients: add pharmacologic prophylaxis once adequate hemostasis is achieved

Case #3

- 59-year-old man with osteoarthritis of the left hip
- Past medical history: COPD
- Plan: left hip replacement

What DVT prophylaxis do you recommend?

Case #3: Knee and Hip Arthroplasty

- Pharmacologic prophylaxis with LMWH preferred
 - Second line alternatives: fondaparinux, apixaban, dabigatran, rivaroxaban, or SQ heparin
 - Third line alternatives: low dose Coumadin, aspirin, or intermittent pneumatic compression
- Minimum of 10-14 days treatment
- If started pre-operatively, start LMWH \geq 12 hours prior to surgery
- Routine screening duplex ultrasound of asymptomatic patients is NOT recommended

Case #4

- 75 year old man admitted with CHF exacerbation
- Past medical history: lung cancer (undergoing radiation therapy), Prior stroke, obesity (BMI 33)
- Past surgical history: Lobectomy 3 weeks ago

What DVT prophylaxis would you recommend?

DVT/PE Risk Factors in Hospitalized Patients

| Risk Factor | Points |
|--------------------------------------|--------|
| Active Cancer | 3 |
| Previous DVT/PE | 3 |
| Reduced mobility | 3 |
| Known Thrombophilia | 3 |
| Surgery in Last Month | 2 |
| Age > 70 | 1 |
| Heart or Respiratory Failure | 1 |
| MI or Stroke | 1 |
| Infection or Rheumatologic Condition | 1 |
| BMI > 30 | 1 |
| Hormonal Treatment | 1 |

Case #4: Hospitalized Medical Patient

- 3 points for active cancer
- 2 points for recent surgery
- 1 point for age > 70
- 1 point for heart failure
- 1 point for obesity

Total = 8 points

- High risk \geq 4 points:
 - LMWH
 - SQ heparin
 - Fondaparinux
- High risk \geq 4 points plus bleeding risk:
 - Intermittent pneumatic compression
- Low risk:
 - No prophylaxis

Case #5

- 60 year old woman admitted to the ICU with respiratory failure due to influenza
- Past medical history: COPD

Should you do a routine screening duplex ultrasound?

What DVT prophylaxis would you recommend?

Case #5: Critically Ill Patient

- Screening ultrasounds NOT recommended
- LMWH or SQ heparin preferred
- Intermittent pneumatic compression in patients with bleeding risks

Case #6

- 48 year old woman with metastatic ovarian cancer undergoing chemotherapy

Should she have DVT prophylaxis as an outpatient?

If an indwelling central line is placed for chemotherapy, should she receive DVT prophylaxis?

Case #6: Outpatients With Cancer (solid tumors)

- Pharmacologic prophylaxis not recommended:
 - No additional risk factors for DVT/PE
- LMWH or SQ heparin recommended:
 - Previous thromboembolism
 - Immobilization
 - Hormonal therapy
 - Angiogenesis inhibitors
 - Thalidomide or lenalidomide
- Indwelling venous ports: prophylaxis not advised